AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04396860 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT01812239 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Progesterone gel.
Description: Daily administration of Vaginal Progesterone gel in pregnant women with twins between the 20th week of pregnancy and the 34th week of pregnancy.
Study NCT01812239 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: fetal fibronectin swab.
Description: Collection of quantatative fetal fibronectin swab one week after randomization into the trial for both arms. Randomziation occurs between 20 weeks - 24 weeks of gestation.
Study NCT01812239 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fetal fibronectin swab.
Description: Collection of quantatative fetal fibronectin swab one week after randomization into the trial for both arms. Randomziation occurs between 20 weeks - 24 weeks of gestation.
Study NCT04396860 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NovoTTF-100A Device
Description: Wear Optune device
Study NCT03832725 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Protein (HP) weight loss diet
Description: Newly diagnosed Type 2 Diabetic (NT2DM) subjects will be placed on a HP diet for 6 months with all food provided for weight loss and remission of NT2DM.~Intervention with the HP diet will be 6 months. If subjects have not had remission of Type 2 Diabetes by the end of the 6 months, they will be referred to an endocrinologist for pharmaceutical treatment
Study NCT01812239 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: weekly vaginal administration of the placebo gel from randomization until 34 weeks of gestation.
Study NCT03543735 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wisepill+SMS
Description: This will include: 1) an in-person Wisepill orientation session to introduce the pillbox and generate relapse prevention messages that can be later delivered during non-adherent windows; 2) use of the Wisepill device during the intensive treatment program and after discharge; and 3) three forms of tailored SMS messages paired with Wisepill device use: a) supportive messages with medication compliance, b) reminder messages for early non-adherence (e.g., 1 hour late) and c) relapse-prevention messages after longer periods of non-adherence (e.g., several hours).
Study NCT03543735 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wisepill-only
Description: This will include: 1) an in-person Wisepill orientation session to introduce the pillbox; 2) use of the Wisepill during the intensive treatment program and after discharge.
Study NCT04396860 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04396860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04396860 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04396860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04396860 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT04396860 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT04396860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Given PO
Study NCT02886065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citarinostat
Description: Citarinostat (180 mg) administered orally once daily on days 1-21 every 28 day cycle.
Study NCT03381651 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Higher dose (50.4Gy/28F) of neoadjuvant chemoradiation
Description: 50.4Gy/28F radiation and concurrent chemotherapy with paclitaxel plus CBP used weekly
Study NCT03381651 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Lower dose (41.4Gy/23F) of neoadjuvant chemoradiation
Description: 41.4Gy/23F radiation and concurrent chemotherapy with paclitaxel plus CBP used weekly
Study NCT03832725 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High carbohydrate (HC) weight loss diet
Description: Newly diagnosed Type 2 Diabetic (NT2DM) subjects will be placed on a HC diet for 6 months with all food provided for weight loss and remission of NT2DM.~Intervention with the HP diet will be 6 months. If subjects have not had remission of Type 2 Diabetes by the end of the 6 months, they will be referred to an endocrinologist for pharmaceutical treatment
Study NCT03760081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1650
Description: Participants received ASP1650 dose level 1 or dose level 2 as intravenous infusion, Q2W starting on C1D1 for up to a maximum of 12 cycles or until study discontinuation criterion was met, whichever occurred earlier. Duration of each treatment cycle was 14 days.
Study NCT01917227 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Study NCT02986139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Commercial Formulation Etanercept
Description: Etanercept was supplied in a single-use SureClick autoinjector as a sterile, preservative-free solution for SC injection containing 0.98 mL of 50 mg/mL etanercept in the commercial formulation.
Study NCT02986139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: New Formulation Etanercept
Description: Etanercept was supplied in a single-use SureClick autoinjector as a sterile, preservative-free solution for SC injection containing 0.98 mL of 50 mg/mL etanercept in the new formulation.
Study NCT02344849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cell
Description: Patients will receive single injection of Cellgram-ED( 30,000,000 mesenchymal stem cell) intracavernously.
Study NCT01216020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: * Cetuximab is given according to the standard mode of administration: loading dose : 400 mg/m2 one week before the start of radiotherapy (week -1), followed by a weekly dose of 250 mg/m2 during the weeks of the treatment with radiotherapy.~* Radiotherapy: Doses: Clinical sites of disease (T e N) : total dose of 70 Gy given with a fractional dose of 2 Gy/day; prophylactic nodal volume (N) : total dose of 50 Gy given with a fractional dose of 2 Gy/day ; Treatment technique: conformal 3D. Intensity modulated radiotherapy (IMRT), also with simultaneous boost (SIB), is allowed.
Study NCT01216020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin (associated to radiotherapy)
Description: * CDDP dose: 40 mg/mq in a single weekly 1-hour infusion preceded by adequate hydration, diuretics e antiemetic premedication.~* Radiotherapy: Doses: Clinical sites of disease (T e N) : total dose of 70 Gy given with a fractional dose of 2 Gy/day; prophylactic nodal volume (N) : total dose of 50 Gy given with a fractional dose of 2 Gy/day ; Treatment technique: conformal 3D. Intensity modulated radiotherapy (IMRT), also with simultaneous boost (SIB), is allowed.
Study NCT03199196 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activity Tracker
Description: Group 1 - Intervention: Participants given an accelerometer at each visit. Participant wears the accelerometer for 7 days.~Group 2 - Newsletters: After completing the 16 week visit, participant given an activity tracker.
Study NCT03199196 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone Application
Description: Group 1 - Intervention: Participant given smartphone application baseline visit to track physical activity, connect with participant's partner to share information about participant's physical activity, and provide support to partner to be more physically active.~Group 2 - Newsletters: After completing the 16 week visit, participant given instruction in the use of a smartphone application.
Study NCT03199196 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Participants complete questionnaires about feelings, moods, motivation for physical activity, any social support received from others, the neighborhood participant lives in, and other physical activity-related topics. Questionnaires completed 1 time at the beginning of the study, 8 weeks after joining the study, and 16 weeks after beginning the study.The questionnaires should take about 45 minutes to complete.
Study NCT03199196 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires
Description: Participants complete questionnaires about feelings, moods, motivation for physical activity, any social support received from others, the neighborhood participant lives in, and other physical activity-related topics. Questionnaires completed 1 time at the beginning of the study, 8 weeks after joining the study, and 16 weeks after beginning the study.The questionnaires should take about 45 minutes to complete.
Study NCT03199196 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focus Group
Description: Participants invited to take part in a final focus group. Focus group takes place sometime after the 16-week visit. Focus groups/interviews are audio recorded.
Study NCT03199196 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Focus Group
Description: Participants invited to take part in a final focus group. Focus group takes place sometime after the 16-week visit. Focus groups/interviews are audio recorded.
Study NCT03199196 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Newsletters
Description: Participant emailed electronic newsletters to read that may help participant be more physically active.
Study NCT03199196 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Electronic Newsletters
Description: Participant emailed electronic newsletters to read that may help participant be more physically active.
Study NCT03199196 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Counseling
Description: Research staff provides telephone counseling to participant and partner biweekly during weeks 1-8 (weeks 1, 3, 5, and 7), and monthly during weeks 9-16 (weeks 11 and 15).
Study NCT02662582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reldesemtiv
Description: Oral tablet
Study NCT02662582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablet
Study NCT02886065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide (25 mg) administered orally once daily on days 1-21 every 28 day cycle.
Study NCT02886065 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PVX-410
Description: PVX-410 Biweekly (0.8 mg) via subcutaneous injection
Study NCT04025281 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Extra Virgin Olive Oil
Description: Participants will consume a meal prepared with 50 mL extra virgin olive oil. The meals will be prepared and provided to the study participants in the cafeteria of Griffin Hospital, where the Prevention Research Center is located. With the exception of the type of olive oil used in the meals, the meal plan will be comparable in all the intervention phases for the same individual.
Study NCT04025281 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Refined Olive Oil
Description: Participants will consume a meal prepared with 50 mL refined olive oil in the cafeteria of Griffin Hospital. With the exception of the olive oil used, the meal plan will be comparable in each the intervention phases for the same individual.
Study NCT04135352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg of pembrolizumab
Description: Participants receive 200 mg of pembrolizumab intravenously Q3W for a maximum of 35 21-day cycles.
Study NCT03997474 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATL001
Description: ATL001 infusion
Study NCT04135352 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V938
Description: Participants receive V938 intratumorally in cycles 1-7. Each cycle is 21 days.
Study NCT03997474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Checkpoint Inhibitor
Description: Nivolumab
Study NCT02867358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KT07 Capsule
Study NCT02867358 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT02867358 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04381871 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acacia Senegal
Description: Oral Digestion of Gum Arabic to be consumed early morning on daily basis for 4weeks
Study NCT04381871 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Pectin
Description: Oral Digestion of Pectin to be consumed early morning on daily basis for 12 weeks
Study NCT01506349 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: gluten
Description: 4 grams of gluten.
Study NCT03004495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF5259 and CHF6001
Description: b.i.d. for 14 days
Study NCT03004495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF5259 + placebo
Description: b.i.d. for 14 days
Study NCT03004495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF6001 + placebo
Description: b.i.d. for 14 days
Study NCT05027893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400 mg Oral Tablet
Description: All used film-coated tablets (400 mg moxifloxacin) were administered for the first five days postoperatively, once a day, after the lower third molar surgery.
Study NCT05027893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefixime 400 mg Oral Tablet
Description: All used film-coated tablets (400 mg cefixime) were administered for the first five days postoperatively, once a day, after the lower third molar surgery.
Study NCT05027893 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All used film-coated placebo-tablets were administered for the first five days postoperatively, once a day, after the lower third molar surgery.
Study NCT03004495 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: b.i.d. for 14 days
Study NCT01506349 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01451541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide nasal aerosol 37 mcg
Description: ciclesonide nasal aerosol 37mcg - the dose is administered as 1 actuation per nostril to give a total dose of 37
Study NCT01451541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ciclesonide nasal aerosol 74 mcg
Description: ciclesonide nasal aerosol 74 mcg - the dose is administered as 1 actuation per nostril to give a total dose of 74 mcg
Study NCT01451541 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - one dose per nostril
Study NCT01799850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: pioglitazone 30 mg daily, pill, eight weeks, placebo randomly assigned
Study NCT01799850 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo assigned randomly, double blind
Study NCT05778890 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Group: Physiotherapy program + home exercises program
Description: Physiotherapy program: The physiotherapy program consisted of 1 session per day for 3 weeks, a total of 15 sessions. Treatment for control group included Ultrasound for 5 minutes to both TMJ, TENS on both TMJ for 20 minutes, exercise for 30 minutes and patient education. In addition to the treatment for control group, intervention group received home exercises program.The intervention group was also taught home exercises program and asked to do 6 repetitions 6 times a day. This exercise program was given to the patients in brochure form.
Study NCT05778890 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group : Physiotherapy program
Description: Physiotherapy program: The physiotherapy program consisted of 1 session per day for 3 weeks, a total of 15 sessions. Treatment for control group included Ultrasound for 5 minutes to both TMJ, TENS on both TMJ for 20 minutes, exercise for 30 minutes and patient education.
Study NCT01634685 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation therapy will be administered daily, Monday-Friday, for a total of 28 treatments, delivered at 1.8 Gy/fraction.
Study NCT01634685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bavituximab
Description: Bavituximab will be delivered concurrently with the radiation therapy for 6 weeks (one time each week), followed by 2 weeks of bavituximab administration by itself.
Study NCT01634685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: capecitabine, will be delivered twice daily p.o. on the days of radiation treatment, at a dose of 825 mg/m2.
Study NCT02701101 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Use of SEM200 Scanner daily
Description: From enrollment to exit,daily SEM Scanner readings collected on Sacrum and Heels
Study NCT02701101 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Assessment and treatment of Pressure Ulcers using SOC
Description: Nurse review of Skin risk and skin assessment, notes in chart to assess the frequency to turn patient, use of a specialist bed to prevent or treat early pressure ulcers
Study NCT02117336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P1446A-05
Description: The study have dose escalation phase, followed by a dose extension phase.~* Dose escalation phase: five Dose Levels will be evaluated in the 'dose escalation' phase. The Dose Levels selected are 50 mg (Dose Level 1), 75 mg (Dose Level 2), 125 mg (Dose Level 3), 200 mg (Dose Level 4) and 275 mg (Dose Level 5), once daily. If required, a 25 mg once daily dose (Dose Level -1) will also be studied. For Dose Levels 1, 2 and 3 there will be 2- dosing periods: Single Dose and Continuous Dose. At least 3-patients will be enrolled at each Dose Level. Dosing regimens planned for Dose Level 4 and 5 are 200 and 275 mg once daily. In the continuous dose period, patients will receive P1446A-05 on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity.~* Dose Extension Phase: Up to a total of 14 patients will be treated at the MTD of P1446A-05, determined in the dose escalation phase, until the occurrence of disease progression or unacceptable toxicity or death.
Study NCT04838093 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PCR
Description: Nasal or pharyngeal respiratory swabs were routinely taken of each patient admitted at our departments and repeated regularly at 48 h intervals during the inpatient stay.~In the HCP cohort testing for SARS-CoV-2 RNA was performed, on a weekly basis, at the Department of Laboratory Medicine, Medical University of Vienna, Austria, using real-time polymerase chain reaction (RT-PCR). Comparability of the results of all test methods used was confirmed by participation in international quality control ring trials.
Study NCT02209207 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill
Study NCT04215991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefiderocol
Description: Administered intravenously over 3 hours
Study NCT04215991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care administered will be selected by the investigator based on the suspected or confirmed pathogen(s) for the infection in accordance with local standards.
Study NCT02209207 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: walking training
Study NCT04215991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of care administered will be selected by the investigator based on the suspected or confirmed pathogen(s) for the infection in accordance with local standards.
Study NCT01237964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiaflex (FDA approved collagenase)
Description: 0.58mg of collagenase will be diluted in saline and injected in 3 points surrounding the limiting contracture
Study NCT01213550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Study NCT01213550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo mouthrinse
Study NCT02511574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: natural progesterone
Study NCT02511574 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cervical pessary
Study NCT02310633 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Memory Strategy Training
Description: This intervention involves intervention that teaches participants to use active encoding strategies to learn and remember new information. The intervention will be implemented using verbal and face-name paired associate learning.
Study NCT03187756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Shortened duration immunosuppression following nonmyeloablative peripheral blood stem cell transplant with high dose post transplantation cyclophosphamide in malignancies to engraft.